BiotechTube
BML, Inc.

BML, Inc.

4694.TPhase 3
2,000-3,000 employeesbml.co.jp

BML, Inc. is a major player in Japan's life science support industry, providing essential testing, research, and diagnostic services to the healthcare and pharmaceutical sectors. The company leverages its extensive laboratory network and technical expertise to support drug development, clinical trials, and routine medical testing. As a publicly traded entity, it maintains a stable financial position while navigating the competitive landscape of clinical testing services. Its strategic focus includes expanding its testing menu, enhancing laboratory automation, and supporting the growing biopharma industry in Japan.

Market Cap
$961.6M
+33.2% period
Pipeline
1
1 in Phase 3
Patents
14
granted
Publications
20
indexed

4694.T · Stock Price

USD 4070.00+1015.00 (+33.22%)

Historical price data

AI Company Overview

BML, Inc. is a major player in Japan's life science support industry, providing essential testing, research, and diagnostic services to the healthcare and pharmaceutical sectors. The company leverages its extensive laboratory network and technical expertise to support drug development, clinical trials, and routine medical testing. As a publicly traded entity, it maintains a stable financial position while navigating the competitive landscape of clinical testing services. Its strategic focus includes expanding its testing menu, enhancing laboratory automation, and supporting the growing biopharma industry in Japan.

Services - Multi-therapeutic

Technology Platform

Integrated clinical laboratory and contract research service platform, utilizing high-throughput automation, advanced analytical techniques (mass spectrometry, genomics), and data management systems to support healthcare diagnostics and pharmaceutical R&D.

Pipeline

1
1 drug in pipeline1 in Phase 3
DrugIndicationStageWatch
macitentan 10 mgChronic Thromboembolic Pulmonary Hypertension (CTEPH)Phase 3

Funding History

1
Total raised:$30M
IPO$30MDec 15, 2002

Opportunities

Growth is driven by Japan's aging population requiring more diagnostic tests, increasing outsourcing of clinical trial services by pharma companies, and expansion into advanced genomic and personalized medicine testing.
The company can leverage its trusted domestic brand to capture more market share.

Risk Factors

Key risks include regulatory changes to health insurance reimbursement for lab tests, economic sensitivity to pharmaceutical R&D spending cycles, intense competition from both domestic and global players, and the risk of technological disruption in laboratory science.

Competitive Landscape

BML's main competitors are domestic clinical lab rivals like SRL, Inc. and global Contract Research Organizations (CROs) like IQVIA and LabCorp. Its differentiation lies in its strong domestic network, deep understanding of the Japanese regulatory environment, and long-standing client relationships within Japan.